GlassScriptPhysician profile
Santsaran C Patel
NPI 1316960016
$1,756.88
in general payments reported to CMS, 2019-2025
27 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $264 · 2024: $83.33 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $210.09 | 2019-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $184.60 | 2019-2020 | |
| Novo Nordisk INC | $134.52 | 2019-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $126.44 | 2019-2020 | |
| Pfizer INC. | $119.46 | 2019 | |
| Boston Scientific Corporation | $114.57 | 2020 | |
| Abbott Laboratories | $104.77 | 2024-2025 | Esprit, Freestyle Libre 3 |
| Amgen INC. | $91.49 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.34 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.68 | 2025 | Caplyta |
| Abbvie INC. | $69.65 | 2019-2025 | |
| Astellas Pharma US INC | $52.47 | 2020-2025 | Veozah |
| Mylan Specialty L.P. | $38.45 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $36.45 | 2019 | |
| Lilly USA, LLC | $33.23 | 2025 | Kisunla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $32.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.81 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $29.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.91 | 2019-2020 | |
| Radius Health, INC. | $27.74 | 2019 | |
| Jazz Pharmaceuticals INC. | $25.46 | 2019 | |
| Glaxosmithkline, LLC. | $23.10 | 2019 | |
| Phathom Pharmaceuticals, INC. | $22.25 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $19.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.65 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.53 | 2019 | |
| Merck Sharp & Dohme LLC | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santsaran Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.